Robert Steven Walters
Residential Contractor at Pleasant Dr, Durham, NC

License number
North Carolina 42226
Renew Date
Jan 25, 2006
Category
General Contractor
Type
Residential
Address
Address
109 Pleasant Dr, Durham, NC 27703
Phone
(919) 961-6453

Personal information

See more information about Robert Steven Walters at radaris.com
Name
Address
Phone
Robert Walters
2567 Mint Julep Dr, Creedmoor, NC 27522
Robert Walters
3561 Sanderling Dr SE, Southport, NC 28461
Robert Walters
254 Horace Walters Rd, Raeford, NC 28376
Robert Walters
404 Old Farm Rd, Raeford, NC 28376
Robert Walters
404 Wayne Ave, Tarboro, NC 27886

Professional information

Robert W Walters Photo 1

Dr. Robert W Walters, Albuquerque NM - MD (Doctor of Medicine)

Specialties:
Dermatology
Address:
Dermatology/Skin Cancer Ctr-NM
6200 Uptown Blvd NE SUITE 410, Albuquerque 87110
(505) 243-7546 (Phone)
Certifications:
Dermatology, 2007
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Dermatology/Skin Cancer Ctr-NM
6200 Uptown Blvd NE SUITE 410, Albuquerque 87110
Duke Health Raleigh Hospital
3400 Wake Forest Rd, Raleigh 27609
Duke University Hospital
2301 Erwin Rd, Durham 27710
Durham Regional Hospital
3643 North Roxboro Rd, Durham 27704
Education:
Medical School
Roy J Lucille a Carver College Of Medicine At University Of Iowa
Graduated: 2003
University Of Iowa Hospitals and Clinics
Duke University Med Center


Robert Walters Photo 2

Nicotinic Acid Receptor Ligands

US Patent:
2011007, Mar 24, 2011
Filed:
May 27, 2009
Appl. No.:
12/736966
Inventors:
Robert J. Lefkowitz - Durham NC, US
Scott M. Dewire - Durham NC, US
Erin J. Whalen - Durham NC, US
Jonathan D. Violin - Durham NC, US
Robert W. Walters - Durham NC, US
International Classification:
A61K 31/455, G01N 33/53, A61P 9/10, A61P 3/06
US Classification:
514356, 436501, 435 72
Abstract:
The present invention relates, in general, to nicotinic acid receptor ligands and, in particular, to ligands that have a relative efficacy for activating a G-protein-coupled receptor function (e.g., signaling) that is greater than their relative efficacy for stimulating β-arrestin function (e.g., recruitment and/or signaling). The invention further relates to the use of such “biased ligands” to decrease triglycerides levels and to potentially increase high density lipoprotein (HDL) levels in patients and potentially lower low density lipoprotein (LDL) and/or very low density lipoprotein (VLDL) levels. In addition, the invention relates to methods of identifying such “biased ligands”.